RT Journal Article
T1 Factory neovessels: engineered human blood vessels secreting therapeutic proteins as a new drug delivery system
A1 Compte, Marta
A1 Alonso-Camino, Vanesa
A1 Cuesta Martínez, Ángel
A1 Santos-Valle, Patricia
A1 Sánchez-Martín, David
A1 López, Mariola
A1 Vicario, José Luis
A1 Salas, Clara
A1 Sanz, Laura
A1 Álvarez-Vallina, Luis
AB Several works have shown the feasibility of engineering functional blood vessels in vivo using human endothelial cells (ECs). Going further, we explored the therapeutic potential of neovessels after gene-modifying the ECs for the secretion of a therapeutic protein. Given that these vessels are connected with the host vascular bed, we hypothesized that systemic release of the expressed protein is immediate. As a proof of principle, we used primary human ECs transduced with a lentiviral vector for the expression of a recombinant bispecific αCEA/αCD3 antibody. These ECs, along with mesenchymal stem cells as a source of mural cells, were embedded in Matrigel and subcutaneously implanted in nude mice. High antibody levels were detected in plasma for 1 month. Furthermore, the antibody exerted a therapeutic effect in mice bearing distant carcinoembryonic-antigen (CEA)-positive tumors after inoculation of human T cells. In summary, we show for the first time the therapeutic effect of a protein locally secreted by engineered human neovessels.
PB Springer Nature
SN 0969-7128
YR 2010
FD 2010
LK https://hdl.handle.net/20.500.14352/93824
UL https://hdl.handle.net/20.500.14352/93824
LA eng
NO Compte M, Alonso-Camino V, Santos-Valle P, et al. Factory neovessels: engineered human blood vessels secreting therapeutic proteins as a new drug delivery system. Gene Ther. 2010;17(6):745-751. doi:10.1038/gt.2010.33
NO Ministerio de Ciencia e Innovación (España)
NO Comunidad de Madrid
NO Fondo de Investigación Sanitaria
NO Instituto de Salud Carlos III
NO Gobierno Vasco
NO European Commission
DS Docta Complutense
RD 16 abr 2025